Coya Therapeutics posts investor presentation on Treg-directed combination therapy for neurodegenerative diseases
COYA•Early ALS study findings
An investor-sponsored ALS study (n=4) showed ALSFRS-R stabilization or improvement over 48 weeks. No deaths or serious adverse events were reported.
Partnership and financial position
Dr. Reddy’s deal covers global ALS rights excluding Japan and Latin America, with up to about USD 700 million in milestones and low-to-mid teens royalties.
Cash was USD 43.2 million as of June 30, 2026. The company said its runway is projected into H2 2027, with about 23,500,000 shares outstanding.
ALSTARS Phase 2 timeline and endpoint
ALSTARS Phase 2 enrollment is expected to finish in H2 2026. The primary endpoint is ALSFRS-R change from baseline to Week 24 versus placebo.
Investor presentation highlights COYA 302 program
Coya Therapeutics highlighted COYA 302 (low-dose IL-2 with CTLA4-Ig) as its lead neurodegeneration program, with an ALS Phase 2 readout expected in Q1 2027.
